-
公开(公告)号:NO20021931D0
公开(公告)日:2002-04-24
申请号:NO20021931
申请日:2002-04-24
Applicant: BASF AG
Inventor: KESSELER MARIA , HAUER BERNHARD , FRIEDRICH THOMAS , MATTES RALF
IPC: C12N15/09 , C12N1/21 , C12N9/16 , C12N9/18 , C12N15/55 , C12P17/04 , C12P41/00 , C12R1/19 , C12N
Abstract: The present invention relates to proteins which have an enzymatic activity for hydrolyzing L-pantolactone. The invention further relates to nucleic acids which code for these proteins, to nucleic acid constructs, vectors, genetically modified microorganisms and to a process for preparing D-pantolactone.
-
公开(公告)号:NO20011912L
公开(公告)日:2001-04-18
申请号:NO20011912
申请日:2001-04-18
Applicant: BASF AG
Inventor: RESS-LOESCHKE MARION , FRIEDRICH THOMAS , HAUER BERNHARD , MATTES RALF , ENGELS DIRK
IPC: C07H21/00 , C12N1/21 , C12N9/78 , C12N15/55 , C12P7/40 , C12P7/42 , C12N15/09 , C12P41/00 , C12R1/05 , C12N5/10
Abstract: The invention relates to nucleic acid sequences which code for a polypeptide having nitrilase activity, to nucleic acid constructs comprising the nucleic acid sequences, and to vectors comprising the nucleic acid sequences or the nucleic acid constructs. The invention further relates to amino acid sequences which are encoded by the nucleic acid sequences, and to microorganisms comprising the nucleic acid sequences, the nucleic acid constructs or vectors comprising the nucleic acid sequences or the nucleic acid constructs.The invention additionally relates to a process for preparing chiral carboxylic acids from the racemic nitriles.
-
公开(公告)号:CA2347521A1
公开(公告)日:2000-04-27
申请号:CA2347521
申请日:1999-10-13
Applicant: BASF AG
Inventor: RESS-LOSCHKE MARION , HAUER BERNHARD , ENGELS DIRK , FRIEDRICH THOMAS , MATTES RALF
IPC: C12N15/09 , C07H21/00 , C12N1/21 , C12N9/78 , C12N15/55 , C12P7/40 , C12P7/42 , C12P41/00 , C12R1/05 , C12N15/63
Abstract: The invention relates to nucleic acid sequences which code for a polypeptide with nitrilase activity, to nucleic acid constructs containing the nucleic acid sequences, and to vectors containing the nucleic acid sequences or the nucleic acid constructs. The invention also relates to amino acid sequences which are coded by the nucleic acid sequences, and to microorganisms containing the nucleic acid sequences, the nucleic acid constructs or vector s containing the nucleic acid sequences or the nucleic acid constructs. In addition, the invention relates to a method for producing chiral carboxylic acids from the racemic nitriles.
-
公开(公告)号:BR9707280A
公开(公告)日:1999-07-20
申请号:BR9707280
申请日:1997-02-11
Applicant: BASF AG
Inventor: RADITSCH MARTIN , FRIEDRICH THOMAS , BOLLSCHWEILER CLAUS , SCHMIDT MARTIN , HOFFKEN HANS WOLFGANG , SCHWEDEN JURGEN , RUBSAMEN KLAUS
IPC: C12N15/09 , A61K31/00 , A61K38/00 , A61K38/46 , A61P7/00 , A61P7/04 , C07K14/47 , C12N9/74 , C12N15/00 , C12N15/57 , C12R1/91 , A61K38/48
Abstract: PCT No. PCT/EP97/00612 Sec. 371 Date Aug. 4, 1998 Sec. 102(e) Date Aug. 4, 1998 PCT Filed Feb. 11, 1997 PCT Pub. No. WO97/29198 PCT Pub. Date Aug. 14, 1997The invention concerns thrombin muteins which have the following differences in their sequences as compared with natural thrombin: (a) the exchange of a Gly after Ala, the Gly being in the sequence environment Tyr-Gly-Phe and having position 558 in natural human thrombin (SEQ ID No. 14); (b) at least one exchange or deletion of the following radicals: (b1) His, located in the sequence environment Ala-His-Cys and having position 363 in natural human thrombin (SEQ ID No. 14); (b2) Asp, located in the sequence environment Arg-Asp-Ile and having position 419 in natural human thrombin (SEQ ID No. 14); (b3) Ser, located in the sequence environment Asp-Ser-Gly and having position 525 in natural human thrombin (SEQ ID No. 14). The invention further concerns the use of these muteins as antidotes.
-
公开(公告)号:AT175117T
公开(公告)日:1999-01-15
申请号:AT92912628
申请日:1992-06-23
Applicant: BASF AG
Inventor: BRAATZ REINHARD , KURTH ROLAND , MENKEL-CONEN ELKE , RETTENMAIER HANSJOERG , FRIEDRICH THOMAS , SUBKOWSKI THOMAS
Abstract: PCT No. PCT/EP92/01412 Sec. 371 Date Dec. 28, 1993 Sec. 102(e) Date Dec. 28, 1993 PCT Filed Jun. 23, 1992 PCT Pub. No. WO93/00924 PCT Pub. Date Jan. 21, 1993.The use of bacterial lipases which show an immunological cross-reaction with the antibodies to the lipase produced by the microorganism Pseudomonas spec. DSM 6483 and/or Pseudomonas cepacia IAM 1057 for producing drugs for the therapy of maldigestion is described.
-
公开(公告)号:ZA9701107B
公开(公告)日:1998-08-11
申请号:ZA9701107
申请日:1997-02-11
Applicant: BASF AG
Inventor: RADITSCH MARTIN , FRIEDRICH THOMAS , BOLLSCHWEILER CLAUS , SCHMIDT MARTIN , HOEFFKEN HANS WOLFGANG , SCHWEDEN JUERGEN , RUEBSAMEN KLAUS
IPC: C12N15/09 , A61K31/00 , A61K38/00 , A61K38/46 , A61P7/00 , A61P7/04 , C07K14/47 , C12N9/74 , C12N15/00 , C12N15/57 , C12R1/91 , C07K , A61K , C07H
CPC classification number: C12N9/6429 , A61K38/00 , C12Y304/21005
-
公开(公告)号:NO983677L
公开(公告)日:1998-08-11
申请号:NO983677
申请日:1998-08-11
Applicant: BASF AG
Inventor: RADITSCH MARTIN , FRIEDRICH THOMAS , BOLLSCHWEILER CLAUS , SCHMIDT MARTIN , H FFKEN HANS WOLFGANG , SCHWEDEN J RGEN , R BSAMEN KLAUS
IPC: C12N15/09 , A61K31/00 , A61K38/00 , A61K38/46 , A61P7/00 , A61P7/04 , C07K14/47 , C12N9/74 , C12N15/00 , C12N15/57 , C12R1/91 , A61K38/48
Abstract: PCT No. PCT/EP97/00612 Sec. 371 Date Aug. 4, 1998 Sec. 102(e) Date Aug. 4, 1998 PCT Filed Feb. 11, 1997 PCT Pub. No. WO97/29198 PCT Pub. Date Aug. 14, 1997The invention concerns thrombin muteins which have the following differences in their sequences as compared with natural thrombin: (a) the exchange of a Gly after Ala, the Gly being in the sequence environment Tyr-Gly-Phe and having position 558 in natural human thrombin (SEQ ID No. 14); (b) at least one exchange or deletion of the following radicals: (b1) His, located in the sequence environment Ala-His-Cys and having position 363 in natural human thrombin (SEQ ID No. 14); (b2) Asp, located in the sequence environment Arg-Asp-Ile and having position 419 in natural human thrombin (SEQ ID No. 14); (b3) Ser, located in the sequence environment Asp-Ser-Gly and having position 525 in natural human thrombin (SEQ ID No. 14). The invention further concerns the use of these muteins as antidotes.
-
公开(公告)号:CA2262506A1
公开(公告)日:1998-02-12
申请号:CA2262506
申请日:1997-07-30
Applicant: BASF AG
Inventor: FRIEDRICH THOMAS , SCHREPP WOLFGANG , FUCHS HARALD
IPC: G01N33/543 , G01Q60/20 , G01B5/20 , G01N33/551 , G01N33/566
Abstract: In an active substance screening process, an active substance is detected by observing changes in a signal (S) by means of a scanning nearfield optical microscope (SNOM). Also disclosed is a device suitable for carrying out this process and comprising the SNOM, a device for receiving single or multiple samples and a control unit.
-
公开(公告)号:DK0610246T3
公开(公告)日:1998-01-12
申请号:DK92920588
申请日:1992-09-23
Applicant: BASF AG
Inventor: BIALOJAN SIEGFRIED , FRIEDRICH THOMAS , KOERWER WOLFGANG , KROEGER BURKHARD
IPC: A61K35/64 , A61K38/00 , A61K38/55 , A61P7/02 , C07K1/14 , C07K14/435 , C07K14/81 , C12N15/09 , C12N15/15 , C12P21/02
Abstract: PCT No. PCT/EP92/02198 Sec. 371 Date Mar. 18, 1994 Sec. 102(e) Date Mar. 18, 1994 PCT Filed Sep. 23, 1992 PCT Pub. No. WO93/09231 PCT Pub. Date May 13, 1993A novel thrombin inhibitory protein from ticks with a molecular weight of about 26000 dalton and the partial amino acid sequences Val-Ala-Lys-Phe-Ala-X-Asn-Ser-Gly-Ser-Glu-Thr-Gly (SEQ ID NO: 8), His-Ala-Y-Phe-Glu (SEQ ID NO: 3), Arg-Val-Ser-Asp-Phe-Glu (SEQ ID NO: 4), Phe-Val-Tyr-Thr-Ile-Glu (SEQ ID NO: 6), where X and Y can be identical or different and each is a naturally occurring amino acid, is suitable for controlling diseases.
-
公开(公告)号:CA2245546A1
公开(公告)日:1997-08-14
申请号:CA2245546
申请日:1997-02-11
Applicant: BASF AG
Inventor: H FFKEN HANS WOLFGANG , SCHWEDEN JUERGEN , RADITSCH MARTIN , FRIEDRICH THOMAS , RUEBSAMEN KLAUS , SCHMIDT MARTIN , BOLLSCHWEILER CLAUS
IPC: C12N15/09 , A61K31/00 , A61K38/00 , A61K38/46 , A61P7/00 , A61P7/04 , C07K14/47 , C12N9/74 , C12N15/00 , C12N15/57 , C12R1/91 , A61K38/48
Abstract: The invention concerns thrombin muteins which have the following differences in their sequences as compared with natural thrombin: (a) the exchange of a Gly after Ala, the Gly being in the sequence environment Tyr-Gly-Phe and having position 558 in natural human thrombin (SEQ ID No. 14); (b) at least one exchange or deletion of the following radicals: (b1) His, located in the sequence environment Ala-His-Cys and having position 363 in natural human thrombin (SEQ ID No. 14); (b2) Asp, located in the sequence environment ArgAsp-Ile and having position 419 in natural human thrombin (SEQ ID No. 14); (b3) Ser, located in the sequence environment Asp-Ser-Gly and having position 525 in natural human thrombin (SEQ ID No. 14). The invention further concerns the use of these muteins as antidotes.
-
-
-
-
-
-
-
-
-